Sernova Corp.
TSX:SVA.TO · Toronto Stock Exchange
-$0.01 today
Vol 0.39M · Avg 0.12M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
TSX:SVA.TO · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$11.8M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.04, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $342.6K -36.6% | $540.3K +21.3% | $445.6K +1.3% | $440.0K +64.7% | $267.2K | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$342.6K +36.6% | -$540.3K -21.3% | -$445.6K -1.3% | -$440.0K -64.7% | -$267.2K | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $7.3M -67.4% | $22.4M -30.7% | $32.3M +90.9% | $16.9M +264.3% | $4.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $7.5M -16.4% | $9.0M +6.1% | $8.5M +8.1% | $7.8M +241.7% | $2.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $14.8M -53.6% | $31.8M -22.6% | $41.1M +66.2% | $24.8M +256.9% | $6.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $342.6K -16.5% | $410.5K +33.1% | $308.5K -29.9% | $440.0K +64.7% | $267.2K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$14.7M +52.8% | -$31.3M +22.2% | -$40.2M -63.8% | -$24.5M -271.8% | -$6.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$15.1M +52.5% | -$31.8M +22.6% | -$41.1M -70.1% | -$24.2M -252.1% | -$6.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $25.6K -93.4% | $388.4K -74.1% | $1.5M +159.9% | $577.3K +718.2% | $70.6K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $754.8K +28.6% | $586.9K +1729.6% | $32.1K -72.8% | $118.0K +102.2% | $58.4K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$711.0K -104.9% | -$347.0K -123.1% | $1.5M +49.5% | $1.0M -7.8% | $1.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$15.8M +50.8% | -$32.2M +18.8% | -$39.6M -62.3% | -$24.4M -250.6% | -$7.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$92.2K -1417.0% | $7.0K +101.1% | -$629.0K -633.1% | $118.0K +102.2% | $58.4K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$15.7M +51.1% | -$32.2M +17.5% | -$39.0M -58.9% | -$24.5M -249.4% | -$7.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +52.0% | -$0 +23.1% | -$0 -44.9% | -$0 -213.6% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +52.0% | -$0 +23.1% | -$0 -44.9% | -$0 -213.6% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $328.3M +6.9% | $307.0M +1.2% | $303.3M +10.9% | $273.6M +11.4% | $245.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $328.3M +6.9% | $307.0M +1.2% | $303.3M +10.9% | $273.6M +11.4% | $245.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Covalon Technologies Ltd.
COV.V
$62.14M
Theralase Technologies Inc.
TLT.V
$59.12M
Leef Brands Inc.
LEEF.CN
$50.40M
MedMira Inc.
MIR.V
$45.61M
Microbix Biosystems Inc.
MBX.TO
$41.25M
Resverlogix Corp.
RVX.TO
$31.70M
Defence Therapeutics Inc.
DTC.CN
$26.96M
The Cannabist Company Holdings Inc.
CBST.NE
$17.47M
Hemostemix Inc.
HEM.V
$9.89M
BriaCell Therapeutics Corp.
BCT.TO
$7.70M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SVA.TO generate?
Sernova Corp. (SVA.TO) reported $0.00 of revenue in fiscal 2025.
Is SVA.TO profitable?
Sernova Corp. (SVA.TO) reported -$15,743,466.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.